Aurobindo Pharma, a leading pharmaceutical company, has released its consolidated financial results for the quarter ended September 2025. The company’s net sales for the quarter stood at Rs 8,285.70 crore, representing a year-over-year (Y-o-Y) growth of 6.28%. This growth is a testament to the company’s strong performance and its ability to navigate the challenges in the pharmaceutical industry.
The company’s revenue growth was driven by a combination of factors, including an increase in sales of its existing products, new product launches, and a strong performance in its international markets. Aurobindo Pharma’s international business, which accounts for a significant portion of its revenue, continued to perform well, with sales growth driven by increasing demand for its products in key markets such as the United States and Europe.
The company’s profitability also improved during the quarter, with its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margin expanding to 18.1% compared to 17.4% in the same quarter last year. This improvement in profitability was driven by a combination of factors, including cost savings, operational efficiencies, and a favorable product mix.
Aurobindo Pharma’s research and development (R&D) expenses for the quarter stood at Rs 444.6 crore, representing a Y-o-Y increase of 14.4%. The company continues to invest in R&D to develop new products and expand its pipeline, which is expected to drive future growth.
The company’s management expressed satisfaction with the quarterly performance, citing the strong growth in sales and profitability. They also highlighted the company’s focus on expanding its product portfolio, improving operational efficiencies, and investing in R&D to drive future growth.
Overall, Aurobindo Pharma’s consolidated financial results for the quarter ended September 2025 demonstrate the company’s ability to deliver strong growth and profitability in a challenging environment. The company’s focus on expanding its product portfolio, improving operational efficiencies, and investing in R&D is expected to drive future growth and position it for long-term success.
Key highlights of the results include:
* Net sales of Rs 8,285.70 crore, up 6.28% Y-o-Y
* EBITDA margin of 18.1%, up from 17.4% in the same quarter last year
* R&D expenses of Rs 444.6 crore, up 14.4% Y-o-Y
* Strong growth in international markets, driven by increasing demand for the company’s products
* Focus on expanding product portfolio, improving operational efficiencies, and investing in R&D to drive future growth.